Salus Life focuses on eye health and marketing nutraceuticals targeting eye diseases, including macular degeneration, glaucoma and others.  Our president, Dr. Robert Snyder, MD, PhD, is an ophthalmologist and surgeon and has been practicing for over 40 years . He was also chairman of the Ophthalmology department at the University of Arizona for 15 yrs before going into private practice.

His efforts have generated the clinical trial data that demonstrates the  efficacy of RetinalPro in targeting age-related macular degeneration, the #1 cause of blindness in the developed countries of the world for those over age 60.

In  the US alone, there are over 15 million people currently diagnosed with AMD and seeking improved treatment options, with another million people being newly diagnosed annually. 

There is a class of nutraceuticals on the market developed based on the AREDS clinical trial protocols that contain vitamins, several minerals, and lutein. This formulation has been demonstrated in trials to delay AMD progression statistically, but does not prevent the disease.  (Ocuvite, PreserVision & generics.) 

MaculaPM™ is designed to go beyond what AREDS accomplished by targeting the health of the retina and specifically the Retinal Pigment Epithelial (RPE) cells with L-DOPA, a natural occurring amino acid.

Clinical trials have shown that L-DOPA (aka Levodopa) improves eye health when given orally to target neovascular or “wet” macular degeneration  (nvAMD), wherein fluid builds up in the macula leading to vision loss and over time blindness.

These trials clearly demonstrated that Levodopa taken orally not only reverses the fluid buildup, but also improves Visual Acuity in a significant % of the patients. (Something no orally taken Rx medicinal has accomplished.)

You may be aware of the anti-VEGF injections administered by retina specialist MD’s that are used for “Wet” AMD patients and offered by several pharmaceutical companies, including Avastin and others.  They help initially, but lose effectiveness over time, usually around 2 years.  The injections are also very costly.

Since the MaculaPM™ formulation  is based on naturally occurring compounds and components, it can be provided to patients as a nutraceutical without the added cost and time delays associated with bringing a pharmaceutical to market.